DCR

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 -2523 [-3570; -1477] /10000
64/171 vs. 99/158